Image Guided Radiotherapy Market Scope And Analysis

Report Code : TIPRE00009118
Category : Life Sciences

No. of Pages : 150

Buy Now

Image Guided Radiotherapy Market Scope, Growth, Size and Share by 2030

Buy Now

Image Guided Radiotherapy Market Report Scope

Report Attribute	Details
Market size in 2022	US$ 1,814.25 Million
Market Size by 2030	US$ 5,650.72 Million
Global CAGR (2022 - 2030)	15.3%
Historical Data	2020-2022
Forecast period	2022-2030
Segments Covered	By Type Product and Services By Application Breast Cancer Lung Cancer Gastrointestinal Cancer Prostrate Cancer Gynecological Cancers Head and Neck Cancer By Imaging Type Magnetic Resonance Imaging Positron Emission Tomography Computed Tomography Imaging By End Users Hospitals Oncology Centers Radiotherapy Centers
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	ViewRay GE Healthcare Hitachi Ltd Siemens AG Koninklijke Philips N V TOSHIBA CORPORATION Varian Medical Systems Inc Vision RT Ltd Elekta AB

Key Player Analysis:

ViewRay, GE Healthcare, Hitachi, Ltd.; Siemens AG, Koninklijke Philips N.V.; TOSHIBA CORPORATION, Varian Medical Systems, Inc.; Vision RT Ltd.; Elekta AB, Accuray Incorporated, and HORIBA Group are among the key players analyzed during the image guided radiotherapy market study.

Recent Developments:

The companies operating in the image guided radiotherapy market highly adopt inorganic and organic strategies such as mergers and acquisitions. A few of the recent market developments are listed below:

In May 2023, Philips expanded its mobile C-arm portfolio with Zenition 10.
In April 2023, GE HealthCare expanded its portfolio of magnetic resonance imaging (MRI) contrast agents with the launch of Pixxoscan. It provides customers with access to two leading macrocyclic molecules: Clariscan (gadoteric acid) and Pixxoscan (gadobutrol).
In June 2023, GE HealthCare announced its plans to expand its PET/MR capabilities with AIR technologies to improve diagnostic precision and simplify treatment evaluation while increasing patient comfort.
In September 2022, China's regulatory authority, the National Medical Products Administration (NMPA), approved the sale and use of ViewRay's MRIdian MRI-guided radiation therapy system.